We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Several clinically approved recombinant erythropoi-etin (rEPO) preparations, such as epoetin-β, epoetin-δ and the epoetin-α derivative, darbepoetin-α, have been commercially produced. Since the expiration of patent protection, a number of novel rEPO biosimilars have been approved on the world market. In 2010, epoetin-κ, which is biosimilar to epoetin-α, was(More)
  • 1